Mourabit Halima, Author at MediaMedic

CCHIO 2024丨Dr. Lin Shen: Key Elements and Challenges in Precision Cancer Therapy

By Mourabit Halima 2024.11.20

From November 14 to 17, 2024, the highly anticipated 2024 Chinese Congress on Holistic Integrative Oncology (CCHIO) was held in Xi’an. The event, hosted by the China Anti-Cancer Association and co-organized by the Shaanxi Anti-Cancer Association and the Institute for Development Strategy of Holistic Integrative Medicine , gathered leading experts in oncology.At the conference, Oncology Frontier had the privilege of interviewing Dr. Lin Shen from Peking University Cancer Hospital. The discussion focused on current hotspots and future directions in digestive cancer research during the era of precision medicine.

2024 CACA Integrated Lung Cancer Conference | Dr. Weimin Li: Tailoring Strategies for Lung Nodule Risk Stratification to Empower Precision Lung Cancer

By Mourabit Halima 2024.11.20

The 2024 CACA Integrated Lung Cancer Conference, hosted by the Chinese Anti-Cancer Association, was held in Zhuhai from October 25 to 26. Focusing on the theme “Gathering Strength, Leading the Future,” the conference brought together prominent experts in the field of lung cancer to discuss critical issues and advancements. Oncology frontier interviewed Dr. Weimin Li from West China Hospital, Sichuan University, who shared insights on the progress and future outlook of precision lung cancer screening in China.

ASCO 2024 | Dr. Chang Liu: Dual Immunotherapy Offers New Options for PD-1 Resistant Gastric Cancer Patients

By Mourabit Halima 2024.11.19

The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting has successfully concluded, showcasing groundbreaking oncology research. Dr. Chang Liu from Professor Lin Shen’s team at Peking University Cancer Hospital presented their study on the efficacy and safety of CCR8 monoclonal antibody LM-108 combined with PD-1 antibody in gastric cancer patients. Professor Shen’s presentation at ASCO sparked significant industry interest. Oncology Frontier invited Dr. Chang Liu to provide an in-depth analysis of this study’s breakthroughs and significance.

9th Academic Symposium of the CCIHPBA丨Dr. Tianqiang Song: Advancements in Perioperative Treatments for Liver Cancer and the Tianjin Experience

By Mourabit Halima 2024.11.19

The 9th Academic Symposium of the Chinese Branch of the International Hepato-Pancreato-Biliary Association (IHPBA) was held in Wuhan from October 25-27, 2024, drawing renowned experts from over 20 countries, including the United States, Germany, France, Russia, and Australia. With more than 50 prominent international scholars, 21 academicians, and over 700 experts in liver, gallbladder, and pancreas oncology, the symposium provided a platform to discuss the latest advancements and standards in liver cancer diagnosis and treatment. Dr. Tianqiang Song from Tianjin Medical University Cancer Institute and Hospital delivered an insightful presentation on “Advancements in Perioperative Treatments for Liver Cancer and the Tianjin Experience.” In a joint interview with Oncology Frontier, Professor Song shared insights into perioperative treatment research and practical experiences.

Case Study丨Dr. Jia Shang: Diagnosis and Treatment of Invasive Fungal Infection in Severe Liver Disease Patients

By Mourabit Halima 2024.11.18

Editor's Note: Invasive fungal infection (IFI) refers to a fungal infection that invades the deep tissues and organs of the human body, causing pathological changes such as tissue damage, organ…

SIBCS 2024 | Hot Topics: China’s Breast Cancer Clinical Practice Controversy & Consensus Voting and a Preview of the 2025 CBCS Guidelines Update

By Mourabit Halima 2024.11.18

From October 17 to 19, 2024, the 18th National Breast Cancer Conference and the 19th Shanghai International Breast Cancer Symposium (SIBCS 2024) took place in Shanghai. During this period, the fourth Controversy & Consensus Consortium (3C) Summit, focusing on clinical practice in Chinese breast cancer, was successfully held. Leading breast cancer experts and patient representatives participated in discussions and voting on updates for the 2025 CBCS Guidelines “Little Red Book.”

A Review of the 2024 CCHIO/AOS International Forum I!

By Mourabit Halima 2024.11.18

Adhering to the core concept of "Integrated Cancer Prevention and Treatment, Winning through Integration," on November 14, 2024, a feast of knowledge on cancer prevention and treatment that brought together domestic and international medical elites, patient representatives, and leaders from all walks of life—The 2024 Chinese Congress on Holistic Integrative Oncology and The 40th Anniversary of China Anti-Cancer Association—grandly opened at the Xi'an International Conference Center.

Dr. Jie’er Ying: Exploring New Pathways for Integrative Rehabilitation in Gastric Cancer to Improve Patient Outcomes

By Mourabit Halima 2024.11.17

The 2024 CACA Integrative Gastric Cancer Conference took place in Wuhan from October 18-19, 2024. Oncology Frontier invited Dr. Jie’er Ying, Chairman of the Chinese Anti-Cancer Association’s Gastric Cancer Integrative Rehabilitation Committee and Head of the Hepatobiliary and Gastric Oncology Department at Zhejiang Cancer Hospital, to discuss the current state and development of integrative rehabilitation for gastric cancer.

AMN 2024| Prof. Wenming Chen Receives AMN Distinguished Achievement Award, Leading China’s Advances in Multiple Myeloma

By Mourabit Halima 2024.11.16

On October 19, 2024, the 8th Asian Myeloma Network (AMN) Summit was held in Seoul, South Korea. At this event, the International Myeloma Foundation (IMF) hosted the AMN Awards Ceremony. Prof. Wenming Chen from Beijing Chaoyang Hospital, Capital Medical University, received the AMN Distinguished Achievement Award, recognizing his significant contributions to the field of multiple myeloma (MM) and China’s progress in this field. Following the ceremony, Hematology Frontier had the privilege of interviewing Professor Chen. He shared his thoughts on this award, the development of the AMN, and his insights and outlook on the current and future treatment landscape for MM.

ASH 2024 | Prof. Xiaohui Zhang’s Team Presents 11 Groundbreaking Studies with 3 Oral Presentations！

By Mourabit Halima 2024.11.16

The 66th American Society of Hematology (ASH) Annual Meeting will be held from December 7-10, 2024, in San Diego, USA. As the world’s largest and most comprehensive international academic conference in hematology, ASH attracts thousands of experts and scholars from around the globe each year, who come to share cutting-edge developments and breakthrough clinical data. At this year’s conference, Prof. Xiaohui Zhang’s team from the Department of Hematology, Peking University People’s Hospital, and the Institute of Hematology, Peking University, will showcase an impressive total of 11 studies, including three selected for oral presentations, underscoring China’s outstanding achievements in hematology research. This preview highlights these three oral presentations, inviting readers to follow the presentation schedules and learn more about the fascinating details and stories behind these impactful studies.